| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 80/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Levetiracetam |
| Appearance | White Powder |
| CAS No. | 102767-28-2 |
| MF | C8h14n2o2 |
| MW | 170.20896 |
Levetiracetam is highly effective in animal models of generalized seizures induced by ignition and chemistry. The exact mechanism of its antiepileptic effects is still unknown, but unlike traditional antiepileptic drugs that act on ion channels or excitatory inhibitory neurotransmitter systems, it does not affect synaptic transmission mediated by cholinergic and glutamatergic neurons at therapeutic concentrations. The anti epileptic mechanism may be:
1) Inhibition of high-voltage activation of pyramidal neurons in the hippocampus per channel.
2) Acting on synaptic vesicle proteins, it inhibits epileptic discharges by regulating the extracellular secretory function of synaptic vesicles and the release of presynaptic neurotransmitters.
3) Reverse the negative conformational changes of receptor antagonists, which indirectly enhance the central inhibitory effect of glycolytic acid on neurons capable of both glycolytic and cholinergic functions.
4) Blocking the downregulation of cortical receptors and retaining the downregulated receptors in the hippocampus enhances the inhibitory effect on neuronal circuits. The latest research shows that levetiracetam can also block neurotransmitter release before synapsis, but the exact mechanism is unclear, possibly by binding to a certain protein selectively expressed on the presynaptic membrane of nerve endings.
5) The receptors in the cerebral cortex can be regulated by reducing the current induced by kainic acid in the air base of kainate and decreasing the amplitude and frequency of micro excitatory postsynaptic currents.
){kind=link}